NAD+: The Cell's Energy Currency and Aging Clock

The short version

NAD+ is not a peptide. It is a small molecule that every living cell depends on to convert food into energy and to run the enzymes that repair DNA and regulate gene expression. Think of it as a rechargeable electron shuttle: it picks up electrons in the metabolic pathways that break down carbohydrates and fats, ferries them to the mitochondria to make ATP, and then gets recharged and goes again. Alongside that day-job as an energy carrier, NAD+ is also consumed — destroyed as a signal — by a family of enzymes called sirtuins and PARPs that sit at the center of the biology of aging.

The key fact about NAD+ and aging is this: tissue levels fall as we get older, partly because the enzyme CD38 rises and devours the pool ^[16]. Raising NAD+ — most rationally through precursor molecules like NMN or NR rather than by swallowing NAD+ itself (which is poorly absorbed intact) — is one of the most actively tested strategies in human longevity research ^[11][12][15]. The evidence is real but more modest than the marketing suggests, and the 2025 review in Nature Metabolism put it plainly: human efficacy data remain limited, and the translation from mice to people is not guaranteed ^[11].

What it is

NAD+ stands for Nicotinamide Adenine Dinucleotide, oxidized form. Its molecular formula is C21H27N7O14P2. It is a dinucleotide: a nicotinamide mononucleotide (NMN) unit linked to an adenosine monophosphate unit through two phosphate bridges. The pyridine ring of the nicotinamide carries the chemistry that matters — it accepts and donates electrons, cycling between the oxidized form (NAD+) and the reduced form (NADH). The same pair exists in a phosphorylated version (NADP+/NADPH) used in biosynthetic reactions.

NAD+ is categorized as a dietary supplement in the wellness and supplement market — it is not a drug, not a peptide, and not a research peptide in the same regulatory category as ipamorelin or MOTS-c. Its precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are what most oral products contain; there is also IV NAD+ used in wellness clinics, though that is compounded and not FDA-approved. There are no brand names to avoid here — generic terms only: NAD+, NMN, nicotinamide riboside.

How it works

NAD+ operates across two major functional roles that become the rationale for interest in supplementation:

As a redox coenzyme: NAD+ accepts hydride ions (a proton plus two electrons) from glycolysis and the tricarboxylic acid (TCA) cycle, becoming NADH, and then delivers those electrons to mitochondrial Complex I to drive oxidative phosphorylation — the cell's main ATP-production machinery. Without adequate NAD+, this entire cascade slows.

As a consumed signaling substrate: Sirtuins (SIRT1 through SIRT7) are NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, DNA repair and stress responses. For every reaction a sirtuin catalyzes, one molecule of NAD+ is destroyed. PARP1 (poly(ADP-ribose) polymerase), the main enzyme that repairs DNA strand breaks, also consumes NAD+ at a prodigious rate during genotoxic stress. These demands compete for the same NAD+ pool ^[14].

Why aging matters: CD38, a NAD+-consuming ectoenzyme that rises with age and inflammation, is the primary driver of the age-related NAD+ decline. In mouse models, CD38 knockout preserves NAD+ levels, protects SIRT3 activity, and improves mitochondrial function with age ^[16]. The practical implication is that supplementing NAD+ precursors might compensate for the sink that CD38 represents — a hypothesis that has generated the human trials described below.

What the research shows

Precursor pharmacology — NR. Nicotinamide riboside (NR) at doses of 100 to 1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively in healthy overweight adults (n=120) in a randomized, double-blind, placebo-controlled trial. No flushing and no significant adverse-event differences from placebo were observed at any dose; LDL cholesterol and 1-carbon metabolism were unaffected ^[15]. This was a safety and pharmacology study, not a clinical outcomes trial.

Precursor pharmacology — NMN. In a multicenter, double-blind, placebo-controlled RCT in 80 middle-aged adults, NMN at 300, 600, and 900 mg/day for 60 days dose-dependently raised blood NAD+, improved walking distance, and improved quality-of-life scores versus placebo; 600 mg/day was identified as the apparent optimum dose. No safety issues were observed at any dose ^[12].

Muscle insulin sensitivity — NMN in women. In a randomized trial of 25 prediabetic postmenopausal women, NMN at 250 mg/day for 10 weeks significantly increased muscle insulin sensitivity (assessed by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling pathways in skeletal muscle biopsies, without changes in body composition or HbA1c ^[13]. A specific metabolic signal in a specific population.

The NAD+ decline biology. A foundational 2021 review in Nature Reviews Molecular Cell Biology identifies the major NAD-consuming enzymes — sirtuins, PARP1, and CD38/CD157 — that compete for the cellular pool and frames restoring NAD+ as a candidate strategy against age-related dysfunction across model organisms ^[14].

Cardiac application. In human myocardium and a mouse model of heart failure with preserved ejection fraction (HFpEF), NAD+ repletion restored the activity of HMGCS2 (the rate-limiting ketogenic enzyme), increased fatty acid oxidation, and rescued cardiac function in an HMGCS2-dependent manner — a 2025 study pointing toward a specific mechanism in cardiovascular disease ^[17].

The honest 2025 synthesis. A 2025 Nature Metabolism review of the entire human evidence base concludes that blood NAD+ elevation by precursors is consistently demonstrated, that age-related NAD+ decline is confirmed in some but not all human tissues, and that the translation to hard clinical endpoints — longevity, disease prevention, functional improvement — remains inconsistent and incompletely proven ^[11]. The mice live longer; the humans get higher blood NAD+ numbers and, in some trials, specific improvements in specific populations. That is the honest state of the field.

Reported effects, cautions & safety

NAD+ and its precursors are broadly well-tolerated in short-term trials, but several cautions are specific and worth stating plainly:

On the oral bioavailability of NAD+ itself: Most experts consider plain oral 'NAD+' capsules largely ineffective as a way to raise intracellular NAD+ — the molecule is poorly absorbed intact. NMN and NR are the rational precursor routes because they enter cells via specific transporters and are converted intracellularly to NAD+. This is a biochemical distinction that marketing frequently blurs.

On IV NAD+: Intravenously administered NAD+ is rapidly cleared from plasma. Infusions at excessive rates can cause chest tightness, abdominal cramping, flushing, and nausea — clinically observed side effects from IV wellness therapy. Compounded injectable NAD+ carries contamination risk: the FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin levels. This is not a theoretical concern.

On cancer biology: NAD+ supports the metabolism of proliferating cells, including cancer cells. A theoretical concern exists that chronically boosting the NAD+ pool could fuel existing tumors. NAD+ plays dual, context-dependent roles in oncology — both supporting cancer and enabling DNA-repair that suppresses it. This nuance is poorly handled in consumer marketing.

On NMN regulatory status: The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was previously investigated as a new drug — creating ongoing marketplace uncertainty in the US. The regulatory landscape may continue to shift.

No community anecdote data is compiled in this desk's source material for NAD+, so none is presented here; cautions above are drawn from the literature ^[11][14].

Where it fits in growth-hormone axis and longevity research

NAD+ is the lead compound on this desk because it represents a different level of the longevity biology hierarchy than the GH secretagogues. Where Ipamorelin and CJC-1295 work by amplifying GH pulses from the pituitary — a hormonal strategy — NAD+ operates at the cellular level: it is the substrate that makes mitochondria run and that sirtuins consume to regulate gene expression and DNA repair. These are not competing theories of aging; they may be complementary layers of the same problem.

Of the four compounds here, NAD+ has the most extensive and most rigorous human trial record. It also carries the most clinical nuance: which precursor, which dose, which tissue, which population. The 2025 review is a useful anchor for what the evidence actually proves versus what it suggests. See how it sits alongside the GH axis compounds on the compare page.